Revvity Inc. logo

Revvity Inc. (RVTY)

Market Closed
3 Mar, 20:00
NYSE NYSE
$
95. 95
+0.36
+0.38%
$
11.15B Market Cap
- P/E Ratio
0.28% Div Yield
909,903 Volume
- Eps
$ 95.59
Previous Close
Day Range
91.19 96.11
Year Range
81.36 120.39
Want to track RVTY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
RVTY earnings report is expected in 54 days (27 Apr 2026)
Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates

Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates

Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago.

Zacks | 1 year ago
Revvity cuts 2024 revenue forecast amid biotech spending slowdown

Revvity cuts 2024 revenue forecast amid biotech spending slowdown

Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development.

Reuters | 1 year ago
Revvity to Report Q3 Earnings: What's in Store for the Stock?

Revvity to Report Q3 Earnings: What's in Store for the Stock?

RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.

Zacks | 1 year ago
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline

Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Revvity Shares Decline Despite Launch of Transcribe AI Solution

Revvity Shares Decline Despite Launch of Transcribe AI Solution

RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.

Zacks | 1 year ago
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease

RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease

Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.

Zacks | 1 year ago
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.

Zacks | 1 year ago
Reasons to Retain Revvity Stock in Your Portfolio for Now

Reasons to Retain Revvity Stock in Your Portfolio for Now

RVTY's strong product portfolio raises optimism about the stock.

Zacks | 1 year ago
MD or RVTY: Which Is the Better Value Stock Right Now?

MD or RVTY: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 1 year ago
MD or RVTY: Which Is the Better Value Stock Right Now?

MD or RVTY: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Revvity (RVTY). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 1 year ago
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised

Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised

Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.

Zacks | 1 year ago
Diagnostic Products Demand Boosts Profit and Sales at Revvity

Diagnostic Products Demand Boosts Profit and Sales at Revvity

Revvity (RVTY) shares advanced Monday after the medical equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidance on higher demand for its diagnostic products.

Investopedia | 1 year ago
Loading...
Load More